Clinical target sequencing for precision medicine of breast cancer.
Breast cancer
Clinical target sequencing
Drug resistance
Next-generation sequencing
Precision medicine
Targeted therapy
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
08
2018
accepted:
19
11
2018
pubmed:
4
1
2019
medline:
14
3
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
Precision medicine can be defined as the customization of medical treatment based on the individual genetic profile, which enables one to identify patients who respond to therapies while sparing side effects for those who do not. Breast cancer patients have been treated based on subtyping, which is considered a prototype of precision medicine. Furthermore, the development of multigene panel testing has resulted in a paradigm shift in the treatment of breast cancer. The knowledge generated from the Human Genome Project, and subsequently The Cancer Genome Atlas, has provided the concept of precision medicine, in which cancer patients can be sub-classified based on actionable driver mutations that can be selectively targeted by molecular targeted drugs and treated by appropriate molecular targeted therapies. Development of next-generation sequencing has both dramatically advanced genomic sequencing technology and revealed actionable driver mutations for individual cancer patients when applied to a clinical setting. Clinical target sequencing by next-generation sequencing enables one to formulate treatment strategies, not only by selecting a subgroup of patients who are expected to experience more effectiveness of each drug, but also by revealing patients with drug resistance based on their actionable driver mutations.
Identifiants
pubmed: 30604156
doi: 10.1007/s10147-018-1373-5
pii: 10.1007/s10147-018-1373-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-140Subventions
Organisme : Japan Society for the Promotion of Science
ID : 16K19888
Organisme : Japan Society for the Promotion of Science
ID : 18K19576
Organisme : Japan Society for the Promotion of Science
ID : 16K15610
Organisme : NIH/NCI grant
ID : R01CA160688
Organisme : Susan G. Komen Investigator Initiated Research Grant
ID : IIR12222224
Références
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7
pubmed: 10430922
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
N Engl J Med. 1976 Feb 19;294(8):405-10
pubmed: 1246307
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
Nature. 2003 Apr 24;422(6934):835-47
pubmed: 12695777
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
BMJ. 2005 Jan 29;330(7485):217
pubmed: 15649903
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Nature. 2005 Sep 15;437(7057):376-80
pubmed: 16056220
Science. 2005 Sep 9;309(5741):1728-32
pubmed: 16081699
Expert Opin Pharmacother. 2005 Aug;6(9):1463-76
pubmed: 16086635
Science. 2005 Dec 9;310(5754):1615
pubmed: 16339428
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3025-6
pubmed: 16576752
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
Clin Chem. 2007 Jun;53(6):1084-91
pubmed: 17463177
Oncologist. 2007 Jun;12(6):631-5
pubmed: 17602054
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Eur J Cancer. 2008 May;44(7):963-71
pubmed: 18362067
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Hastings Cent Rep. 2010 Sep-Oct;40(5):14-6
pubmed: 20964158
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Nat Rev Clin Oncol. 2011 Dec 06;9(1):48-57
pubmed: 22143140
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Clin Cancer Res. 2012 Apr 15;18(8):2402-12
pubmed: 22351696
Cancer Discov. 2012 Jan;2(1):82-93
pubmed: 22585170
Cancer Discov. 2011 Jun;1(1):44-53
pubmed: 22586319
Clin Cancer Res. 2012 Aug 15;18(16):4465-72
pubmed: 22711706
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cancer Discov. 2013 Jan;3(1):27-34
pubmed: 23319768
Nat Med. 2013 Mar;19(3):249
pubmed: 23467220
Nat Med. 2013 Jun;19(6):655
pubmed: 23744135
J Clin Oncol. 2013 Aug 1;31(22):2783-90
pubmed: 23816962
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
J Mol Diagn. 2014 Jan;16(1):56-67
pubmed: 24189654
Int J Cancer. 2015 Jul 15;137(2):262-6
pubmed: 24789362
BMC Med. 2014 Aug 12;12:132
pubmed: 25285786
N Engl J Med. 2015 Feb 26;372(9):793-5
pubmed: 25635347
J Natl Cancer Inst. 2015 Feb 06;107(4):null
pubmed: 25663694
J Clin Oncol. 2015 Mar 20;33(9):975-7
pubmed: 25667288
J Natl Cancer Inst. 2015 Apr 11;107(7):null
pubmed: 25863335
Mol Diagn Ther. 2015 Jun;19(3):169-77
pubmed: 25926090
Cell Rep. 2015 Jun 16;11(10):1549-63
pubmed: 26051943
Clin Cancer Res. 2016 Feb 1;22(3):560-6
pubmed: 26152740
Am J Mens Health. 2017 Jul;11(4):1124-1129
pubmed: 26186950
Nat Rev Clin Oncol. 2015 Dec;12(12):693-704
pubmed: 26196250
Genome Med. 2015 Jul 29;7(1):80
pubmed: 26221189
Nat Rev Drug Discov. 2015 Aug;14(8):513-5
pubmed: 26228747
Nat Biotechnol. 2015 Aug;33(8):790-1
pubmed: 26252121
Drug Discov Today. 2015 Dec;20(12):1422-8
pubmed: 26320725
Chin Clin Oncol. 2015 Sep;4(3):31
pubmed: 26408298
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
BMC Med. 2015 Dec 18;13:303
pubmed: 26684470
Pharmgenomics Pers Med. 2016 Jan 22;9:7-16
pubmed: 26858530
Theor Biol Med Model. 2016 Feb 29;13:7
pubmed: 26925829
Cancer Cell. 2016 Mar 14;29(3):243-244
pubmed: 26977873
Cancer Cell. 2016 Mar 14;29(3):255-269
pubmed: 26977878
N Engl J Med. 2016 May 19;374(20):1901-4
pubmed: 27043262
J Clin Oncol. 2016 Jun 20;34(18):2115-24
pubmed: 27091708
J Clin Pharmacol. 2016 Dec;56(12):1484-1499
pubmed: 27197880
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Trends Pharmacol Sci. 2017 Jan;38(1):25-40
pubmed: 27871777
Genome Med. 2016 Dec 22;8(1):136
pubmed: 28007036
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Breast Cancer Res Treat. 2017 Feb;162(1):191-198
pubmed: 28062977
Ann Oncol. 2017 Jan 1;28(1):34-43
pubmed: 28177494
J Mol Diagn. 2017 Mar;19(2):313-327
pubmed: 28188106
Hum Pathol. 2017 Aug;66:1-9
pubmed: 28235632
J Cancer Res Clin Oncol. 2017 Jul;143(7):1255-1262
pubmed: 28247034
Eur J Health Econ. 2018 Apr;19(3):341-353
pubmed: 28382503
Am J Pathol. 2017 Oct;187(10):2133-2138
pubmed: 28734944
Ann Surg Oncol. 2017 Oct;24(10):2943-2949
pubmed: 28766230
Genome Med. 2017 Oct 31;9(1):93
pubmed: 29089060
Sci Rep. 2017 Nov 21;7(1):15945
pubmed: 29162923
Oncotarget. 2017 Aug 24;8(55):93567-93579
pubmed: 29212173
Oncotarget. 2017 Oct 6;8(59):99978-99989
pubmed: 29245954
Clin Genet. 2018 Mar;93(3):533-544
pubmed: 29265354